LOS ANGELES — This city is now home to its very first biotech venture firm: Dr. Beth Seidenberg, a general partner at Kleiner Perkins, will now be heading up a $320 million fund called Westlake Village BioPartners dedicated exclusively to the life sciences — and, potentially, helping build up the LA area as a new biotech hub.

Seidenberg, former chief medical officer of Amgen, is bringing on board Sean Harper — who by January will end his tenure as R&D head at the Los Angeles-area biotech. Some of the better-known companies in Seidenberg’s portfolio include ovarian cancer therapeutics company Tesaro, allogeneic T cell company Atara Biotherapeutics, and epigenetics player Epizyme.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy